Dear Editor, Tigecycline is an expanded broad-spectrum antibiotic used to treat complicated skin infections or complicated intraabdominal infections [1] . We report a case in which the use of tigecycline was associated with a severe coagulation disorder which resolved rapidly and completely after discontinuing the drug.
A 54-year-old female patient with end-stage renal disease (ESRD) undergoing continuous ambulatory peritoneal dialysis contracted a second episode of peritonitis (Escherichia coli, Klebsiella oxytoca, and Candida albicans). Markers of systemic inflammation were markedly elevated (white blood cell count 19.3 G/l, C-reactive protein 34.1 mg/dl). The patient was in a reduced general condition. Imaging studies failed to demonstrate an intestinal perforation. The initial anti-infective regime consisted of imipeneme/cilastin and fluconazole. The peritoneal catheter was removed and the patient was switched to hemodialysis. However, the peritonitis did not improve. Therefore, diflucan was switched to anidulafungin and tigecycline was added. Of note is that the patient did not have an underlying hepatic disease [2] . Consecutively, signs of systemic inflammation and the patient's condition improved. Therefore, carbapenem/cilastin (after 29 days) and anidulafungin (after 27 days) were stopped and tigecycline was continued (overlap with the other two anti-infective agents for about 3 weeks). However, imaging studies revealed the formation of an intra-abdominal abscess which was partially drained under computed tomography guidance. During the course, a slow but progressive deterioration of coagulation parameters was noted [international normalized ratio increased to 3.08, activated partial thromboplastin time (aPTT) increased from 30.5 to >160 s; normal range (NR), 23.0-31.9 s]. These changes were refractory to vitamin K supplementation. In addition, there were high levels of D-dimer (14.18 mg/l; NR, 0-0.5 mg/l), reduced levels of antithrombin III (AT III; 28%; NR, 75-125%), and severe hypofibrinogenenmia (28 mg/dl; NR, 180-400 mg/dl). These changes are in line with a severe coagulation disturbance which has also some of the characteristics of disseminated intravascular coagulation, a condition which might develop in a patient with severe peritonitis [3] . However, there was a certain level of distrust since the coagulation disorder became more severe while signs of inflammation improved. In addition, platelets remained within the normal range, and the patient did not demonstrate any signs of end-organ damage due to microthrombosis nor was there evidence of bleeding.
As we suspected an association with the prolonged use of tigecycline, we discontinued the drug despite the abscess. From the next day on, aPTT (normalized within 6 days), AT III (37% after 4 days), and fibrinogen improved markedly (normalized within 5 days). The strong timedependent association of the coagulation disorder and the prolonged use of tigecycline and its reversal after discontinuation (Table 1 ) might point to a causative role of the drug. Previously, a prolonged aPTT during treatment with tigecycline was noted [2] . The FDA mentions vitamin K deficiency due to the effects on the flora of the intestine as one of the possible mechanisms [4] . This can be excluded in the given case as the patient received vitamin K supplementation. Further speculated mechanisms are direct drug effects on the clotting cascade and drug-related hypoproteinemia. It is recommended to monitor aPTT in patients receiving warfarin and tigecycline [2, 5] . However, to date, no case has been reported in which there was lifethreatening hypofibrinogenemia and prolongation of aPTT and INR. Whether the patient's ESRD and/or the long treatment duration (total of 39 days) may have influenced the results remains open.
In conclusion, we believe that monitoring INR, aPTT, and fibrinogen should be considered in all patients receiving tigecycline, especially if the treatment will last for a longer duration. If patients do develop hypofibrinogenemia, one should consider stopping tigecycline. 
